Suzhou Bluehorse Therapeutics Co., Ltd.

This phase 2 trial tests a new treatment called LM103 TILs for people with advanced melanoma that has not responded to at least two prior therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then infused back to attack the cancer. The…